Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Omeros (NASDAQ:OMER)

EMA rejects Omeros' Yartemlea for TA-TMA, citing insufficient efficacy data, despite FDA approval and U.S. launch.

Raccontata dabenzinga.com